glp 1/gip receptor agonist New strategies for the treatment of obesity and metabolic dysfunctions GIP and GLP‐1, the two

In earlier studies, retatrutide reduced liver fat by more than 80% in people with metabolic fatty liver disease, with most participants no longer meeting diagnostic thresholds

Glucagon increases blood glucose levels, particularly during fasting, and facilitates the mobilization of energy reserves.Synthetic agonists like semaglutide and tirzepatide are stable peptides that specifically activate the receptors of these hormones, amplifying their beneficial effects on glycemic control and weight management

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

Some even suggest that GLP-1 agonists might have the potential to supplant MASH therapy in its entirety

What happens when you stop taking GLP-1s like Ozempic and Wegovy

But from 2030, Pfizer could emerge as a credible Top-3 obesity player if both the injectable and oral combo strategies succeed